Medical AI

Masimo's FDA-cleared AI monitor for opioid risk does more than track vitals; it predicts danger, pushing healthcare from reactive alarms to proactive intervention.

GuideAI Health's new AI software, which scans for peripheral vascular disease, promises to slash diagnosis times and prevent amputations for millions.

A startup just raised $5M for an AI that teaches cells to be better factories. It's a glimpse into a future of cheaper, faster advanced medicines for all.

Genialis's new BioBridge platform uses AI to de-risk the $137B flow of oncology drugs from China to the West, a critical test of resilience.

A California clinic known for ketamine bets on the booming NAD+ IV market. As wellness clinics expand, experts question if the science supports the high price tag.

Digital health innovator Light AI has secured C$5M to navigate the regulatory maze. Can its AI platform truly revolutionize diagnostics from our pockets?

uniQure's early trial data for AMT-260 shows promise in reducing severe seizures, but experts urge cautious optimism on the long road to a cure.

For decades, insomnia treatment meant risky sedatives. Now, a new class of drugs is revolutionizing sleep science, promising safer rest for millions.

A new alliance aims to get an FDA-cleared device for a painful chemo side effect into patients' hands, tackling the hidden barriers of healthcare logistics.

New real-time imaging gives surgeons a 3D molecular map of cancer in the OR, poised to end the emotional and physical toll of reoperations for many.

For years, CIDP patients faced limited options. Now, a wave of targeted therapies promises to transform treatment, sparking a multi-billion dollar market boom.

A silent health crisis affecting a billion women is becoming a major economic focus. One firm's move to train a new workforce signals a paradigm shift.

Nuwellis bets on educating hundreds of physicians on its Aquadex system, a high-stakes strategy to combat fluid overload and secure its place in medicine.

A new grant from The Michael J. Fox Foundation highlights a radical approach to Parkinson's: targeting astrocytes to restore balance and halt neurodegeneration.

With a key webinar ahead, Arrowhead Pharma is showcasing a trio of gene-silencing drugs. Can its TRiM™ platform upend a multi-billion dollar cardiometabolic market?

At BIO 2026, Transpire Bio isn't just presenting; it's pitching a new paradigm for medicine, using inhalation to tackle everything from diabetes to cancer.

A half-million dollar grant is just the start. A new public-private alliance is mobilizing to fight blast-induced brain injuries. Here's the story behind the numbers.

German biotech Mallia Aesthetics reports impressive results for its hormone-free hair serum, but the real story lies in its resilient, science-first strategy.

As Oncoinvent accelerates its Phase 2 trial, a novel alpha-emitter therapy shows promise against a deadly cancer, signaling progress in radiopharmaceuticals.